Aliases:This biomarker is also known as:
- versican proteoglycan,
- Large fibroblast proteoglycan,
- Chondroitin sulfate proteoglycan core protein 2,
- Glial hyaluronate-binding protein,
- versican core protein,
- chondroitin sulfate proteoglycan 2,
VCAN, or CSPG2, a large chondroitin sulfate proteoglycan, is a major component of the extracellular matrix. This secreted protein is involved in cell adhesion, proliferation, migration and angiogenesis and plays a central role in tissue morphogenesis and maintenance. It is may play a role in intercellular signaling. Mutations in the CSPG2 gene are the cause of Wagner syndrome type 1. Multiple transcript variants encoding different isoforms have been found for this gene.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
VCAN (CSPG2) was shown to localize to vascular-like structures in ovarian cancer but not in normal ovaries.
VCAN, or CSPG2, was one of 13 genes out of 50 selected for further validation in PMID:21617380. Average expression of VCAN was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.
|UniProt Accession #:||P13611|
|Mutated Sites Count:||1133|
|Associated Pubmed ID Count||43|
|Affected Protein Function Sites Count:||5|